The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, held their first face-to-face meeting since December 2019 in Brussels on Monday 21 and Tuesday 22 June, to discuss global health challenges and public health policies impacting biomedical innovation.
Read moreIFPMA welcomes the opportunity to address this meeting of the Essential Medicines List (EML) Expert Committee, and we take this occasion to also congratulate the World Health Organization (WHO) for the progress made over 44 years in the iterations of the Essential Medicines List. IFPMA represents over 30 leading global biopharmaceutical companies and 50 national...
Read moreThis oped was originally published on in the Down to Earth (16-30 June 2021 Edition). Scarcity of raw materials and trade barriers could dent hopes for 10 billion vaccines produced by end of 2021 Back in March 2020, vaccine innovator companies started working on how they would set up manufacturing and the supply chains produce...
Read moreOriginal article published on Taggesspigel on 15 June 2021. Mr Cueni, of all things, the COVID-19 pandemic, triggered by a virus, could further fuel the development of resistance in bacteria: many Covid 19 patients in hospitals are given antibiotics unnecessarily. G-7 health ministers are warning of a “creeping pandemic” and have been pushing for the...
Read moreAt the 3 June meeting, the life science industry leaders agreed to join forces with governments to step up collective efforts to ensure the world is better prepared to tackle future global pandemics.
Read moreG7 country dose sharing announcements on the back of the G20 pledges combined with vaccine makers commitment to make available 3,5 billion extra doses are an important starting point towards achieving vaccine equity. Innovative vaccine manufacturers and biotech companies at the forefront producing COVID-19 vaccines are confident if scarcity of raw materials and trade barriers...
Read moreOn World Anti-counterfeit day, 10 June 2021, the IFPMA hosted a joint event with local Pharmaceutical Industry Associations from across the African continent to tackle the topic of falsified medicines and chart a robust response to eliminate falsified medicines in the region.
Read moreThe COVID-19 pandemic has led to a global surge in reported falsified medical products including personal protective equipment, diagnostic tests, and more recently falsified or substandard medicines, “cures” and vaccines.
Read moreTalking to CNBC-TV18’s Parikshit Luthra (4 June 2021), IFPMA Director General Thomas Cueni shared his perspective on global vaccine supplies. Main interview highlights from Thomas Cueni: We from IFPMA called out to governments across the world to join us in a five-step plan to urgently address vaccine equity. The first ask is dose sharing. There...
Read moreThe global pharmaceutical industry welcomes the G7 Health and Finance meeting communiqués and the commitment to address antimicrobial resistance (AMR), one of the top 10 global public health threats facing humanity. While tackling the COVID-19 pandemic is an urgent global health priority, AMR continues annually to be responsible for 700,000 deaths, and the numbers are...
Read moreThis oped has been originally published on The Telegraph on 3rd June 2021. Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) In 2016, the United States National Security Council[1]drew up a playbook on fighting pandemics so that the next response to...
Read moreLandmark collaboration between Government and life sciences industry leaders to join mission to protect against future pandemic threats and slash time to develop and deploy new diagnostics, therapeutics and vaccines to 100 days. Intention to work towards the ambition of a 100 Days Mission follows crucial discussions at UK-hosted G7 Health Ministers’ and life sciences...
Read more